Lantern Pharma Achieves Milestone in Phase 2 HARMONIC Trial for Non-Smoker NSCLC Patients in Japan
Lantern Pharma completes targeted enrollment for its Phase 2 HARMONIC trial in Japan, marking a significant step in its international expansion and offering hope for never-smoker NSCLC patients.
Lantern Pharma (NASDAQ: LTRN), a pioneer in AI-driven oncology drug development, has successfully completed the targeted enrollment for its Phase 2 HARMONIC clinical trial in Japan ahead of schedule. This trial, focusing on never-smoker non-small cell lung cancer (NSCLC) patients who have progressed after tyrosine kinase inhibitors, has enrolled 10 patients across five sites, including the prestigious National Cancer Center Japan. The trial evaluates the efficacy of LP-300 in combination with carboplatin and pemetrexed, building on promising early U.S. data that showed an 86% clinical benefit rate, including a durable complete response lasting nearly two years.
The completion of enrollment in Japan is a testament to Lantern Pharma's strategic international expansion into regions with a higher prevalence of never-smoker NSCLC, such as Japan and Taiwan, where enrollment continues alongside U.S. sites. CEO Panna Sharma highlighted this milestone as a validation of the company's approach to leveraging its proprietary RADR(R) platform, which utilizes over 100 billion oncology-focused data points and a library of 200+ advanced machine learning algorithms to accelerate drug discovery and development.
The global HARMONIC trial aims to enroll approximately 90 patients, offering a beacon of hope for a patient population with limited treatment options. The success of this trial could significantly impact the treatment landscape for never-smoker NSCLC patients, potentially providing a life-changing therapy. For more details on the trial and Lantern Pharma's innovative approach to oncology drug development, visit https://ibn.fm/IcDma.
Lantern Pharma's commitment to transforming the cost, pace, and timeline of oncology drug discovery and development through AI and machine learning is evident in its growing pipeline of therapies. With an estimated combined annual market potential of over $15 billion USD, the company's efforts could benefit hundreds of thousands of cancer patients worldwide. For the latest updates on Lantern Pharma, visit https://ibn.fm/LTRN.